Ticker

Santhera Pharmaceuticals Holding AG (OTCMKTS:SPHDF - Get Free Report)'s stock price was up 35.4% during mid-day trading on Tuesday. The company traded as high as $22.04 and last traded at $22.04. Approximately 2,000 shares changed hands during mid-day trading, an increase of 43% from the average daily volume of 1,400 shares. The stock had

November 3, 2025, should have registered as a turning point for Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0). Yet, the date passed with little market fanfare, even though it marked the release of top-line results from the company's GUARDIAN study, data that promises to reshape the treatment landscape for Duchenne muscular dystrophy.

BlackRock Inc (NYSE:BLK) reported fourth quarter 2025 earnings that exceeded Wall Street expectations and ended the year with a record $14 trillion in...

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy in patients aged four years and older. The company expects to launch AGAMREE in Switzerland in the second half of 2026, following completion of pricing and reimbursement procedures.

Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0) told investors it has received approval from Swissmedic for AGAMREE® (vamorolone) for the treatment...